Travere Therapeutics (NASDAQ:TVTX) CAO Sandra Calvin Sells 7,402 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 7,402 shares of the business’s stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $40.00, for a total value of $296,080.00. Following the transaction, the chief accounting officer owned 38,233 shares of the company’s stock, valued at approximately $1,529,320. This represents a 16.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Sandra Calvin also recently made the following trade(s):

• On Tuesday, November 4th, Sandra Calvin sold 67,115 shares of Travere Therapeutics stock. The shares were sold at an average price of $36.00, for a total value of $2,416,140.00.

Travere Therapeutics Stock Down 1.9%

Shares of Travere Therapeutics stock opened at $38.88 on Tuesday. The company has a debt-to-equity ratio of 4.23, a current ratio of 2.75 and a quick ratio of 2.71. Travere Therapeutics, Inc. has a 1-year low of $12.91 and a 1-year high of $42.13. The business’s fifty day moving average price is $34.36 and its two-hundred day moving average price is $24.61. The company has a market capitalization of $3.48 billion, a P/E ratio of -36.68 and a beta of 0.89.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Thursday, October 30th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.59. Travere Therapeutics had a negative return on equity of 178.68% and a negative net margin of 20.32%.The company had revenue of $164.86 million for the quarter, compared to analyst estimates of $106.09 million. During the same period last year, the company earned ($0.70) earnings per share. The company’s quarterly revenue was up 162.1% compared to the same quarter last year. As a group, research analysts forecast that Travere Therapeutics, Inc. will post -1.4 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Arizona State Retirement System increased its holdings in shares of Travere Therapeutics by 1.5% in the third quarter. Arizona State Retirement System now owns 24,964 shares of the company’s stock valued at $597,000 after buying an additional 375 shares in the last quarter. Prudential Financial Inc. grew its holdings in shares of Travere Therapeutics by 0.3% in the 2nd quarter. Prudential Financial Inc. now owns 244,256 shares of the company’s stock worth $3,615,000 after acquiring an additional 615 shares during the last quarter. Teacher Retirement System of Texas raised its position in shares of Travere Therapeutics by 3.5% during the second quarter. Teacher Retirement System of Texas now owns 22,688 shares of the company’s stock worth $336,000 after purchasing an additional 773 shares during the period. Diversified Trust Co lifted its holdings in shares of Travere Therapeutics by 3.5% during the third quarter. Diversified Trust Co now owns 23,695 shares of the company’s stock valued at $566,000 after purchasing an additional 796 shares during the last quarter. Finally, Sio Capital Management LLC lifted its holdings in shares of Travere Therapeutics by 1.0% during the second quarter. Sio Capital Management LLC now owns 122,210 shares of the company’s stock valued at $1,809,000 after purchasing an additional 1,210 shares during the last quarter.

Wall Street Analyst Weigh In

A number of analysts have commented on TVTX shares. Piper Sandler boosted their price target on shares of Travere Therapeutics from $26.00 to $35.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Citigroup raised their price objective on shares of Travere Therapeutics from $34.00 to $48.00 and gave the company a “buy” rating in a research note on Friday, October 31st. TD Cowen upped their target price on Travere Therapeutics from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Cowen reaffirmed a “buy” rating on shares of Travere Therapeutics in a research note on Friday, October 31st. Finally, Jefferies Financial Group set a $35.00 price objective on Travere Therapeutics in a research note on Wednesday, September 10th. Thirteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $38.71.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.